Literature DB >> 28007303

Innate immune regulation of autoimmunity in multiple sclerosis: Focus on the role of Toll-like receptor 2.

Md Jakir Hossain1, Radu Tanasescu2, Bruno Gran3.   

Abstract

Innate immunity relies on a set of germline-encoded receptors including Toll-like receptors (TLRs) that enable the host to discriminate between self and non-self. Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system (CNS). Infections are thought to play an important role in disease susceptibility. The role of innate immunity in MS has been recently appreciated. TLR2, a member of the TLR family, forms heterodimers with either TLR1 or TLR6 and detects a wide range of microbial as well as self-derived molecular structures. It may thus be important both in fighting infection and in activating autoimmunity. In this review, we discuss innate regulation of autoimmunity in MS with a focus on the role of TLR2 signaling.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoimmunity; Inflammation; Innate immunity; Multiple sclerosis; Toll-like receptor 2

Mesh:

Substances:

Year:  2016        PMID: 28007303     DOI: 10.1016/j.jneuroim.2016.12.004

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  16 in total

Review 1.  Understanding the Role of Innate Immunity in the Response to Intracortical Microelectrodes.

Authors:  John K Hermann; Jeffrey R Capadona
Journal:  Crit Rev Biomed Eng       Date:  2018

2.  Toll-Like Receptor 2-Mediated Glial Cell Activation in a Mouse Model of Cuprizone-Induced Demyelination.

Authors:  Stefan Esser; Larissa Göpfrich; Kai Bihler; Eugenia Kress; Stella Nyamoya; Simone C Tauber; Tim Clarner; Matthias B Stope; Thomas Pufe; Markus Kipp; Lars-Ove Brandenburg
Journal:  Mol Neurobiol       Date:  2017-12-29       Impact factor: 5.590

Review 3.  The Price of Immune Responses and the Role of Vitamin D in the Inner Ear.

Authors:  Béla Büki; Heinz Jünger; Yan Zhang; Yunxia Wang Lundberg
Journal:  Otol Neurotol       Date:  2019-07       Impact factor: 2.311

4.  Prioritization of risk genes in multiple sclerosis by a refined Bayesian framework followed by tissue-specificity and cell type feature assessment.

Authors:  Andi Liu; Astrid M Manuel; Yulin Dai; Zhongming Zhao
Journal:  BMC Genomics       Date:  2022-05-11       Impact factor: 4.547

5.  The neurosteroid pregnenolone promotes degradation of key proteins in the innate immune signaling to suppress inflammation.

Authors:  Subathra Murugan; Padmaja Jakka; Swapna Namani; Varadendra Mujumdar; Girish Radhakrishnan
Journal:  J Biol Chem       Date:  2019-01-15       Impact factor: 5.157

6.  The Soluble Form of Toll-Like Receptor 2 Is Elevated in Serum of Multiple Sclerosis Patients: A Novel Potential Disease Biomarker.

Authors:  Md Jakir Hossain; Elena Morandi; Radu Tanasescu; Nanci Frakich; Marzia Caldano; David Onion; Tola A Faraj; Clett Erridge; Bruno Gran
Journal:  Front Immunol       Date:  2018-03-14       Impact factor: 7.561

Review 7.  Strategies used by helicobacter pylori to establish persistent infection.

Authors:  Amin Talebi Bezmin Abadi
Journal:  World J Gastroenterol       Date:  2017-04-28       Impact factor: 5.742

8.  Anti-inflammatory Effects of Curcumin in Microglial Cells.

Authors:  Yangyang Yu; Qian Shen; Yihong Lai; Sun Y Park; Xingmei Ou; Dongxu Lin; Meiling Jin; Weizhen Zhang
Journal:  Front Pharmacol       Date:  2018-04-20       Impact factor: 5.810

Review 9.  Toll-Like Receptor Signaling Pathways: Novel Therapeutic Targets for Cerebrovascular Disorders.

Authors:  Rezan Ashayeri Ahmadabad; Zahra Mirzaasgari; Ali Gorji; Maryam Khaleghi Ghadiri
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

10.  Dietary Fiber Pectin Directly Blocks Toll-Like Receptor 2-1 and Prevents Doxorubicin-Induced Ileitis.

Authors:  Neha M Sahasrabudhe; Martin Beukema; Lingmin Tian; Berit Troost; Jan Scholte; Erik Bruininx; Geert Bruggeman; Marco van den Berg; Anton Scheurink; Henk A Schols; Marijke M Faas; Paul de Vos
Journal:  Front Immunol       Date:  2018-03-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.